{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Trusha Adeshara",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "NCIT": "^C\\d+$",
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns",
      "CONSO": "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns",
      "DOID": "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns",
      "EFO": "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
    },
    "path": "receptors/echeverria2012.bel",
    "pybel_version": "0.14.10"
  },
  "links": [
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The progressive loss of memory in AD patients correlates with increased levels of Abeta and the deterioration of the cholinergic system in the brain.",
      "key": "711c1e7d1554f962285e07aae0e2457f",
      "line": 80,
      "relation": "increases",
      "source": 64,
      "target": 69
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This deterioration commonly includes a reduction in the levels of acetylcholine (ACh) and alpha3, alpha4, and alpha7 nicotinic ACh receptors (nAChRs) as well as a decrease in the activity of choline acetyltranferase in the brain [5].",
      "key": "ea40dbbe1ab0b619d1051f0867aa05b2",
      "line": 89,
      "relation": "decreases",
      "source": 64,
      "target": 3
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This deterioration commonly includes a reduction in the levels of acetylcholine (ACh) and alpha3, alpha4, and alpha7 nicotinic ACh receptors (nAChRs) as well as a decrease in the activity of choline acetyltranferase in the brain [5].",
      "key": "aa50f15bf7a9bcb1871e0467bb3b46e3",
      "line": 90,
      "relation": "decreases",
      "source": 64,
      "target": 42
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This deterioration commonly includes a reduction in the levels of acetylcholine (ACh) and alpha3, alpha4, and alpha7 nicotinic ACh receptors (nAChRs) as well as a decrease in the activity of choline acetyltranferase in the brain [5].",
      "key": "99dfe4edd8183ed665d58d3171b4b879",
      "line": 91,
      "relation": "decreases",
      "source": 64,
      "target": 43
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This deterioration commonly includes a reduction in the levels of acetylcholine (ACh) and alpha3, alpha4, and alpha7 nicotinic ACh receptors (nAChRs) as well as a decrease in the activity of choline acetyltranferase in the brain [5].",
      "key": "2130552cafebc1cf32d20bcf395f93dd",
      "line": 92,
      "relation": "decreases",
      "source": 64,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "966b0218dd25dc2216ee503c99342b32",
      "line": 99,
      "relation": "association",
      "source": 64,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Because decreased levels of these receptors have been found in AD brains [58], this reduction is considered to explain, at least in part, the cognitive deﬁcits in AD.",
      "key": "2d1e650b88c66df0b178ce9155c11b97",
      "line": 263,
      "relation": "decreases",
      "source": 64,
      "target": 44
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This deterioration commonly includes a reduction in the levels of acetylcholine (ACh) and alpha3, alpha4, and alpha7 nicotinic ACh receptors (nAChRs) as well as a decrease in the activity of choline acetyltranferase in the brain [5].",
      "key": "d4c0eca16d47928c7f4e8833cd3f2d34",
      "line": 93,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 64,
      "target": 41
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "A negative correlation between tobacco use and the incidence of AD has been reported [22].",
      "key": "805a33efafa48408f631de13205b387b",
      "line": 125,
      "relation": "negativeCorrelation",
      "source": 64,
      "target": 72
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Because decreased levels of these receptors have been found in AD brains [58], this reduction is considered to explain, at least in part, the cognitive deﬁcits in AD.",
      "key": "9f0ad5596bc8f60f7c51d7938e8ca5c0",
      "line": 264,
      "relation": "decreases",
      "source": 64,
      "target": 28
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The progressive loss of memory in AD patients correlates with increased levels of Abeta and the deterioration of the cholinergic system in the brain.",
      "key": "7483313a0d6aff1b7e3ca62767bb1376",
      "line": 82,
      "relation": "positiveCorrelation",
      "source": 69,
      "target": 1
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The progressive loss of memory in AD patients correlates with increased levels of Abeta and the deterioration of the cholinergic system in the brain.",
      "key": "a6f818b6c27b693fac69c3f491e370ba",
      "line": 83,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 69,
      "target": 59
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The progressive loss of memory in AD patients correlates with increased levels of Abeta and the deterioration of the cholinergic system in the brain.",
      "key": "41a2487378238b36847e5fab8cea4b13",
      "line": 82,
      "relation": "positiveCorrelation",
      "source": 1,
      "target": 69
    },
    {
      "key": "57c081c7f417ef51a784d9fcba480553",
      "relation": "partOf",
      "source": 1,
      "target": 30
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "There is evidence suggesting that Aβ, which accumulates in the brain of AD patients, has a high afﬁnity for the α7 receptors [10], acting as both an agonist [11] and an antagonist [12] at these receptors.",
      "key": "d8b7bd444e528e273df4c6c09bf8f566",
      "line": 108,
      "relation": "increases",
      "source": 1,
      "target": 30
    },
    {
      "key": "3b2993d3deadf580cbedaf3249aaa09c",
      "relation": "partOf",
      "source": 1,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This concept, though still controversial, is supported by the fact that the level of soluble Abeta correlates better with dementia than does plaque burden in AD patients [101, 102].",
      "key": "bc49cff4f77bc559ab80946a622afaa7",
      "line": 418,
      "relation": "positiveCorrelation",
      "source": 1,
      "target": 66
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The progressive loss of memory in AD patients correlates with increased levels of Abeta and the deterioration of the cholinergic system in the brain.",
      "key": "0affc823d55e75d0eeb53791e52ea69e",
      "line": 83,
      "relation": "negativeCorrelation",
      "source": 59,
      "subject": {
        "modifier": "Activity"
      },
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The positive effect of nicotine on attention has been mostly attributed to its agonistic stimulation of the nAChRs, which plays an important role in mediating memory and attention processes [29–31].",
      "key": "ca6074c40e42301db30e3aafa49defa0",
      "line": 152,
      "relation": "association",
      "source": 59,
      "subject": {
        "modifier": "Activity"
      },
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The positive effect of nicotine on attention has been mostly attributed to its agonistic stimulation of the nAChRs, which plays an important role in mediating memory and attention processes [29–31].",
      "key": "595b201f230e6a941ef56ab9f6508c08",
      "line": 153,
      "relation": "association",
      "source": 59,
      "subject": {
        "modifier": "Activity"
      },
      "target": 20
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "e50e06d7cbc7a49c4edc4f4e4e78e003",
      "line": 99,
      "relation": "association",
      "source": 44,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "582f440e0bd2deb8db6a10301506b011",
      "line": 100,
      "relation": "association",
      "source": 44,
      "target": 67
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "33deb78b0f655b4f8fbb1af82c9dee23",
      "line": 101,
      "relation": "association",
      "source": 44,
      "target": 65
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "04465b39adbe145e14fb2de61e220c88",
      "line": 102,
      "relation": "association",
      "source": 44,
      "target": 71
    },
    {
      "key": "71fa9275fa851c6f8aa9c0b4b7169405",
      "relation": "partOf",
      "source": 44,
      "target": 30
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "3e3166b222e6b95ddae729c6bfd96f44",
      "line": 238,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 44,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "3a100f1869a00eeb898f9fa44ef32a0d",
      "line": 306,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 44,
      "subject": {
        "modifier": "Activity"
      },
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "b218818a81648c698c8b09e7f5923013",
      "line": 320,
      "relation": "increases",
      "source": 44,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "168658000b4ec7ade9350c676d9186fe",
      "line": 239,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 44,
      "target": 50
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Cerebral Cortex": true,
          "Hippocampus": true,
          "Hypothalamus": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 and alpha4beta2 nAChR subtypes are the most abundant of the nicotinic receptors and are fundamental for mediating working memory and attention in mammals. These receptors are localized throughout the cortex, hippocampus, amygdala, hypothalamus, striatum, and other regions involved in these cognitive processes [13].",
      "key": "ed2171f00bc936552af26706e090f534",
      "line": 252,
      "relation": "increases",
      "source": 44,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 receptors are very important for mediating sensory gating, attention and learning, and memory, making them an ideal target to improve these cognitive functions.",
      "key": "ada445df1167b1c3fb17800b02e3c1a6",
      "line": 272,
      "relation": "increases",
      "source": 44,
      "target": 17
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Cerebral Cortex": true,
          "Hippocampus": true,
          "Hypothalamus": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 and alpha4beta2 nAChR subtypes are the most abundant of the nicotinic receptors and are fundamental for mediating working memory and attention in mammals. These receptors are localized throughout the cortex, hippocampus, amygdala, hypothalamus, striatum, and other regions involved in these cognitive processes [13].",
      "key": "e333fe64d693ce1e3593fa00c87d3d51",
      "line": 253,
      "relation": "increases",
      "source": 44,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 receptors are very important for mediating sensory gating, attention and learning, and memory, making them an ideal target to improve these cognitive functions.",
      "key": "74700e55227850b27f4ad2da0f1cf953",
      "line": 273,
      "relation": "increases",
      "source": 44,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Because decreased levels of these receptors have been found in AD brains [58], this reduction is considered to explain, at least in part, the cognitive deﬁcits in AD.",
      "key": "8c5cd43ca01905f5a72c30d8deb0a70d",
      "line": 265,
      "relation": "increases",
      "source": 44,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 receptors are very important for mediating sensory gating, attention and learning, and memory, making them an ideal target to improve these cognitive functions.",
      "key": "9f605c8997b919b0eb82298f83d8181e",
      "line": 271,
      "relation": "increases",
      "source": 44,
      "target": 24
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "b984fffcefddf054668d91c2f82540d6",
      "line": 313,
      "relation": "increases",
      "source": 44,
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "98039dba2e18ec8eb46e7fe7a39603bd",
      "line": 319,
      "relation": "increases",
      "source": 44,
      "target": 57
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "3b680459e4000e7571595a8f2b065280",
      "line": 321,
      "relation": "increases",
      "source": 44,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "204dc7da94508f95802a8afb2af531e5",
      "line": 322,
      "relation": "increases",
      "source": 44,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "1731ae6b34a8002b46fe4e4b31e552c6",
      "line": 323,
      "relation": "increases",
      "source": 44,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The activation of PI3K heterodimers p85/p110 by the α7 receptor is triggered by the binding of p85 (the regulatory subunit) to phospho-tyrosyl proteins such as Fyn, which leads to the release of p110 [the catalytic subunit; Ref. 82].",
      "key": "02a3dcbcbcdde43a6b3b2b0a00b74d6b",
      "line": 343,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 44,
      "target": 58
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The α7 receptors seem to have a clear role in mediating Arc gene expression, as an increase in levels of Arc mRNA were found in rats treated with the selective α7 receptor partial agonist SSR180711 [96].",
      "key": "8e15ee8bf3e55825a9f5b41731b1a785",
      "line": 410,
      "relation": "positiveCorrelation",
      "source": 44,
      "target": 77
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The α7 receptors seem to have a clear role in mediating Arc gene expression, as an increase in levels of Arc mRNA were found in rats treated with the selective α7 receptor partial agonist SSR180711 [96].",
      "key": "2da58840175ff57930451f53e7d0e4c5",
      "line": 411,
      "relation": "increases",
      "source": 44,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "851aa0e8dfcca4d89321c470c001244a",
      "line": 100,
      "relation": "association",
      "source": 67,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "43d4aca8e5b363a7bdd2be95aeff25f9",
      "line": 101,
      "relation": "association",
      "source": 65,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of these nAChRs, the alpha7 receptors are considered to be ideal therapeutic targets for several neurological conditions, including AD, schizophrenia, and Parkinson’s disease (PD) as well as tobacco addiction [6, 7].",
      "key": "e2ff153a065772edf51282bdf2260f8f",
      "line": 102,
      "relation": "association",
      "source": 71,
      "target": 44
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "There is evidence suggesting that Aβ, which accumulates in the brain of AD patients, has a high afﬁnity for the α7 receptors [10], acting as both an agonist [11] and an antagonist [12] at these receptors.",
      "key": "3d110ab36b4f64606ad098c33b1c2b53",
      "line": 109,
      "relation": "increases",
      "source": 30,
      "target": 44
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "There is evidence suggesting that Aβ, which accumulates in the brain of AD patients, has a high afﬁnity for the α7 receptors [10], acting as both an agonist [11] and an antagonist [12] at these receptors.",
      "key": "1db071c460118e69949ed1fbbee9fe7d",
      "line": 110,
      "relation": "decreases",
      "source": 30,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Another current therapeutic approach aims to decrease glutamate excitotoxicity by blocking the N-methyl D-aspartate (NMDA) glutamate receptor using the receptor antagonist memantine.",
      "key": "5c1cc6c30584c45cd46606ec9fffa676",
      "line": 117,
      "relation": "decreases",
      "source": 5,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Another current therapeutic approach aims to decrease glutamate excitotoxicity by blocking the N-methyl D-aspartate (NMDA) glutamate receptor using the receptor antagonist memantine.",
      "key": "ea6ce50f860753062bb9d6bc5812342d",
      "line": 118,
      "relation": "isA",
      "source": 5,
      "target": 0
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Another current therapeutic approach aims to decrease glutamate excitotoxicity by blocking the N-methyl D-aspartate (NMDA) glutamate receptor using the receptor antagonist memantine.",
      "key": "644066840d1be739420302696d242704",
      "line": 119,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 60,
      "target": 2
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "5220741f3748007bc36c32079ade776b",
      "line": 394,
      "relation": "increases",
      "source": 60,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Another current therapeutic approach aims to decrease glutamate excitotoxicity by blocking the N-methyl D-aspartate (NMDA) glutamate receptor using the receptor antagonist memantine.",
      "key": "57c3c159a17e9ccee55b8ac9548c5d0a",
      "line": 120,
      "relation": "increases",
      "source": 2,
      "subject": {
        "modifier": "Activity"
      },
      "target": 63
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "A negative correlation between tobacco use and the incidence of AD has been reported [22].",
      "key": "7a45135e2918530d0c5e4b5e10d58e04",
      "line": 125,
      "relation": "negativeCorrelation",
      "source": 72,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Nicotine binds to Abeta, blocking its aggregation into ﬁbrils and is thereby neuroprotective [23].",
      "key": "fe1e1d0e65feb3160f444f9b76d2d993",
      "line": 130,
      "relation": "decreases",
      "source": 29,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Nicotine binds to Abeta, blocking its aggregation into ﬁbrils and is thereby neuroprotective [23].",
      "key": "51d099ea158ec64f3eca788d72b56d34",
      "line": 131,
      "relation": "decreases",
      "source": 29,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Nicotine binds to Abeta, blocking its aggregation into ﬁbrils and is thereby neuroprotective [23].",
      "key": "9a8ce81538d277f65dc9cc25712ba8ae",
      "line": 132,
      "relation": "increases",
      "source": 29,
      "target": 27
    },
    {
      "key": "deb333ff1b890c06f0fbdc4182988bb1",
      "relation": "partOf",
      "source": 6,
      "target": 29
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Nicotine also diminishes AD pathology in animal models of the disease [24, 25].",
      "key": "f766f46d216ffaf21bed94958f191ee3",
      "line": 139,
      "relation": "decreases",
      "source": 6,
      "target": 64
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true,
          "Parkinson's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "However, clinical studies that aimed to determine the efﬁcacy of nicotine against AD pathology have not shown a signiﬁcant effect of nicotine in enhancing memory [26, 27] but rather a clear positive effect on attention in AD [27] and PD patients [25, 28].",
      "key": "dd831cb4e2ccd2400d09361400c50994",
      "line": 145,
      "relation": "positiveCorrelation",
      "source": 6,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The positive effect of nicotine on attention has been mostly attributed to its agonistic stimulation of the nAChRs, which plays an important role in mediating memory and attention processes [29–31].",
      "key": "109c69abc59c2c4e81a62823cd58788f",
      "line": 151,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 6,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "However, the failure of nicotine to improve memory in AD patients, its inherent toxicity, and the fact that it induces tachyphylaxis and addiction have discouraged its use in the clinical arena [32].",
      "key": "886db146ba97f9af5cd28d4ac20eee38",
      "line": 159,
      "relation": "causesNoChange",
      "source": 6,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "However, the failure of nicotine to improve memory in AD patients, its inherent toxicity, and the fact that it induces tachyphylaxis and addiction have discouraged its use in the clinical arena [32].",
      "key": "7e7ce61fe56c2c489ddfdff2639effa8",
      "line": 161,
      "relation": "increases",
      "source": 6,
      "target": 76
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "However, the failure of nicotine to improve memory in AD patients, its inherent toxicity, and the fact that it induces tachyphylaxis and addiction have discouraged its use in the clinical arena [32].",
      "key": "2e67f0de47b328e907f5591c6248d530",
      "line": 162,
      "relation": "increases",
      "source": 6,
      "target": 75
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "However, the failure of nicotine to improve memory in AD patients, its inherent toxicity, and the fact that it induces tachyphylaxis and addiction have discouraged its use in the clinical arena [32].",
      "key": "5703df2863a5ea0ee8540d060960ff96",
      "line": 163,
      "relation": "increases",
      "source": 6,
      "target": 71
    },
    {
      "key": "e3d0c83671a43b23a0f9e80e79cec334",
      "relation": "partOf",
      "source": 6,
      "target": 32
    },
    {
      "key": "bf5b58aea77e079f63996d22e7024507",
      "relation": "partOf",
      "source": 6,
      "target": 33
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true,
          "Parkinson's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "However, clinical studies that aimed to determine the efﬁcacy of nicotine against AD pathology have not shown a signiﬁcant effect of nicotine in enhancing memory [26, 27] but rather a clear positive effect on attention in AD [27] and PD patients [25, 28].",
      "key": "cbf4bb29804241d6d1f7dba51e84af70",
      "line": 145,
      "relation": "positiveCorrelation",
      "source": 73,
      "target": 6
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The positive effect of nicotine on attention has been mostly attributed to its agonistic stimulation of the nAChRs, which plays an important role in mediating memory and attention processes [29–31].",
      "key": "acb91efab9bc87111017cb2fbca3d5e6",
      "line": 152,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 73,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The positive effect of nicotine on attention has been mostly attributed to its agonistic stimulation of the nAChRs, which plays an important role in mediating memory and attention processes [29–31].",
      "key": "223a1225301d77d387eb78d3579c9fed",
      "line": 153,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 20,
      "target": 59
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Speciﬁcally, it has been shown that cotinine prevented working and reference memory loss in a mouse model of AD (Tg6799) and prevented Aβ aggregation in vitro as well as plaque deposition in vivo [33].",
      "key": "eef32a004f34578f247e70fadc495c81",
      "line": 170,
      "relation": "decreases",
      "source": 15,
      "target": 69
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Speciﬁcally, it has been shown that cotinine prevented working and reference memory loss in a mouse model of AD (Tg6799) and prevented Aβ aggregation in vitro as well as plaque deposition in vivo [33].",
      "key": "0195186f0807cc0aa08f5be11532bb43",
      "line": 172,
      "relation": "decreases",
      "source": 15,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "In addition to its mnemonic qualities, cotinine has anti-Aβ aggregation properties that add to its value as a new treatment for AD [33].",
      "key": "dfcdd5c5c61e57d81d2ed1947164b68a",
      "line": 208,
      "relation": "decreases",
      "source": 15,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10900": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The pro-cognitive effect of cotinine in the Tg6799 mice may be explained by the reduction in the level of the aggregated forms of Aβ, including Aβ plaques and oligomeric forms of the peptide, in the hippocampus and cortex [33].",
      "key": "3011bdc0b68a3c51e95a2227a1138141",
      "line": 217,
      "relation": "decreases",
      "source": 15,
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Speciﬁcally, it has been shown that cotinine prevented working and reference memory loss in a mouse model of AD (Tg6799) and prevented Aβ aggregation in vitro as well as plaque deposition in vivo [33].",
      "key": "45a3b285cde308a84916bf07b4486fd5",
      "line": 173,
      "relation": "decreases",
      "source": 15,
      "target": 70
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10900": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The pro-cognitive effect of cotinine in the Tg6799 mice may be explained by the reduction in the level of the aggregated forms of Aβ, including Aβ plaques and oligomeric forms of the peptide, in the hippocampus and cortex [33].",
      "key": "2ecbc175e9045428645a14e6d5d3863d",
      "line": 218,
      "relation": "decreases",
      "source": 15,
      "target": 70
    },
    {
      "annotations": {
        "Anatomy": {
          "liver": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Cotinine, is mostly metabolized by the liver to its major metabolites, trans-3’hydroxycotinine and its glucuronide [39–41].",
      "key": "d86adf53cf6dfc0d12c63194b7633fba",
      "line": 188,
      "relation": "increases",
      "source": 15,
      "target": 16
    },
    {
      "annotations": {
        "Anatomy": {
          "liver": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Cotinine, is mostly metabolized by the liver to its major metabolites, trans-3’hydroxycotinine and its glucuronide [39–41].",
      "key": "1bfb811314085ebbdad500200f158321",
      "line": 189,
      "relation": "increases",
      "source": 15,
      "target": 14
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "More recently, we and other laboratories have found that cotinine is a memory enhancer in various animal models of disease.",
      "key": "a64887af03264e5c1cf7f67f11ae1789",
      "line": 195,
      "relation": "increases",
      "source": 15,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Also, we recently published evidence showing that cotinine (5 mg/kg) decreased anxiety and enhanced the extinction of contextual fear memory after fear conditioning in wild type mice [50].",
      "key": "2aaece8b1345a71558bf5e4f255e0448",
      "line": 201,
      "relation": "decreases",
      "source": 15,
      "target": 68
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Also, we recently published evidence showing that cotinine (5 mg/kg) decreased anxiety and enhanced the extinction of contextual fear memory after fear conditioning in wild type mice [50].",
      "key": "2ebc7bc95f63e71bb10b35594fb6d761",
      "line": 202,
      "relation": "decreases",
      "source": 15,
      "target": 74
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10900": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The pro-cognitive effect of cotinine in the Tg6799 mice may be explained by the reduction in the level of the aggregated forms of Aβ, including Aβ plaques and oligomeric forms of the peptide, in the hippocampus and cortex [33].",
      "key": "4413adc636e83209a2b101554963ca54",
      "line": 215,
      "relation": "increases",
      "source": 15,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10900": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The pro-cognitive effect of cotinine in the Tg6799 mice may be explained by the reduction in the level of the aggregated forms of Aβ, including Aβ plaques and oligomeric forms of the peptide, in the hippocampus and cortex [33].",
      "key": "f1368874747ca576979a2c7b9ded546f",
      "line": 219,
      "relation": "decreases",
      "source": 15,
      "target": 10
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For instance, cotinine induced the activation of the pro-survival protein kinase B (Akt)/glycogen synthase kinase 3beta (GSK3beta) pathway in the brains of both Tg6799 and wild type control mice, suggesting that the activation of these factors is independent from its effect on Aβ aggregation [33].",
      "key": "f90f09dc9b169bb4af5d9241ce8a5cbc",
      "line": 228,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 35
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Contrary to this idea, new evidence shows that chronic treatment with cotinine stimulates the Akt/GSK3β pathway in the hippocampus and cortex of AD and control littermate mice [33].",
      "key": "5d091e56a477272b5d1f4531afa3c276",
      "line": 296,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 35
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For instance, cotinine induced the activation of the pro-survival protein kinase B (Akt)/glycogen synthase kinase 3beta (GSK3beta) pathway in the brains of both Tg6799 and wild type control mice, suggesting that the activation of these factors is independent from its effect on Aβ aggregation [33].",
      "key": "c7cfbfbd3b736e356d83674352f551da",
      "line": 229,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Contrary to this idea, new evidence shows that chronic treatment with cotinine stimulates the Akt/GSK3β pathway in the hippocampus and cortex of AD and control littermate mice [33].",
      "key": "b30bb94ea10e16932b002d245cc2f1a5",
      "line": 297,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 50
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of equal importance, because GSK3β is considered to be one of the main tau kinases in vivo, the inhibition of GSK3β by cotinine may also prevent the abnormal phosphorylation of tau observed in AD brains and the consequent appearance of neuroﬁbrillary tangles of hyperphosphorylated tau [85–87].",
      "key": "f97b5a241d8458da42d92b83786ff9a2",
      "line": 371,
      "relation": "decreases",
      "source": 15,
      "target": 50
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Cotinine is weak agonist of the α7 receptor, and whether this receptor is the main target of cotinine is still controversial [72].",
      "key": "9098f139e13f5bef7e723beeb6c298c7",
      "line": 288,
      "relation": "increases",
      "source": 15,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "e84afb3e7118e5154ca1770dbdd418f8",
      "line": 305,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 44
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of equal importance, because GSK3β is considered to be one of the main tau kinases in vivo, the inhibition of GSK3β by cotinine may also prevent the abnormal phosphorylation of tau observed in AD brains and the consequent appearance of neuroﬁbrillary tangles of hyperphosphorylated tau [85–87].",
      "key": "4ba08c4203a4f89ed8bb1ddd1216f1f2",
      "line": 373,
      "relation": "decreases",
      "source": 15,
      "target": 56
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of equal importance, because GSK3β is considered to be one of the main tau kinases in vivo, the inhibition of GSK3β by cotinine may also prevent the abnormal phosphorylation of tau observed in AD brains and the consequent appearance of neuroﬁbrillary tangles of hyperphosphorylated tau [85–87].",
      "key": "9b59d7ee92d2f8f546484cb1e82cc663",
      "line": 374,
      "relation": "decreases",
      "source": 15,
      "target": 61
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "e0d3cab3dc0ca93c64f23f9421d1f8d3",
      "line": 381,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "c3a38700dbb9d81f08e81f336f85b952",
      "line": 382,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 54
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "effc5104e7ccc1616ceaea657f794027",
      "line": 383,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 15,
      "target": 53
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "In humans, more than 80% of nicotine is metabolized to cotinine by cytochrome P450 2A6 (CYP2A6) [34] and cytochrome P450 2A5 (CYP2A5) [35] enzymes [36].",
      "key": "5f93e1354b72c085f491c624650c6340",
      "line": 180,
      "relation": "increases",
      "source": 32,
      "target": 15
    },
    {
      "key": "b61368ca0e93f164f2dc0ddde8c5b3cc",
      "relation": "partOf",
      "source": 46,
      "target": 32
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "In humans, more than 80% of nicotine is metabolized to cotinine by cytochrome P450 2A6 (CYP2A6) [34] and cytochrome P450 2A5 (CYP2A5) [35] enzymes [36].",
      "key": "f57374922b85a76969a85f6512987a75",
      "line": 181,
      "relation": "increases",
      "source": 33,
      "target": 15
    },
    {
      "key": "90553e4de10b46e4eabecc05926c3c76",
      "relation": "partOf",
      "source": 62,
      "target": 33
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For instance, cotinine induced the activation of the pro-survival protein kinase B (Akt)/glycogen synthase kinase 3beta (GSK3beta) pathway in the brains of both Tg6799 and wild type control mice, suggesting that the activation of these factors is independent from its effect on Aβ aggregation [33].",
      "key": "2e5e2263e51252485fd5aa64afc9b1e7",
      "line": 230,
      "relation": "causesNoChange",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "d704d6f1944c81a6418610a32f2a9295",
      "line": 240,
      "relation": "decreases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "e5d4087cbefeb7dd49baa006f58558f5",
      "line": 242,
      "relation": "increases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "0f30ca90771f5207b2c5d3f61e6fcd5e",
      "line": 325,
      "relation": "increases",
      "source": 35,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "68faf571df7fc2b16a497a5402ca10b7",
      "line": 244,
      "relation": "increases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 22
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "f0ff0dcde33142dca98fc5caa20c5401",
      "line": 307,
      "relation": "increases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "4a609c9dbbab778ebe5ffc26fe190f89",
      "line": 308,
      "relation": "increases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "daa4e4a9c1c41c8c00c58c64c65b5c5e",
      "line": 309,
      "relation": "increases",
      "source": 35,
      "subject": {
        "modifier": "Activity"
      },
      "target": 47
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "65ad6d5a4736ee87580aa6d28a405dfd",
      "line": 330,
      "relation": "increases",
      "source": 35,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "b3cfd7b607702d5e8e573b89dcdb85b8",
      "line": 335,
      "relation": "increases",
      "source": 35,
      "target": 17
    },
    {
      "key": "56844c59ee0dfe5f65f7145924837d31",
      "relation": "hasVariant",
      "source": 35,
      "target": 37
    },
    {
      "key": "9cc9f44833c2060d52c8e71fc4595958",
      "relation": "hasVariant",
      "source": 35,
      "target": 36
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For instance, cotinine induced the activation of the pro-survival protein kinase B (Akt)/glycogen synthase kinase 3beta (GSK3beta) pathway in the brains of both Tg6799 and wild type control mice, suggesting that the activation of these factors is independent from its effect on Aβ aggregation [33].",
      "key": "89f72a4ddcf9763a96e75b11a411d588",
      "line": 231,
      "relation": "causesNoChange",
      "source": 50,
      "subject": {
        "modifier": "Activity"
      },
      "target": 8
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "f06139dfd468893507166cac3dbf2e70",
      "line": 241,
      "relation": "decreases",
      "source": 50,
      "subject": {
        "modifier": "Activity"
      },
      "target": 18
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "8a3dd24cf8fb121a5d9f7be17bb68de4",
      "line": 243,
      "relation": "increases",
      "source": 50,
      "subject": {
        "modifier": "Activity"
      },
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": " Interestingly, the Akt/GSK3β pathway is stimulated by the alpha7 receptor, has roles inhibiting neuronal cell death, and is involved in promoting neuronal synaptic plasticity and long-term potentiation [53–55].",
      "key": "3f32fdf3be308b85f84889b9f7396012",
      "line": 245,
      "relation": "increases",
      "source": 50,
      "subject": {
        "modifier": "Activity"
      },
      "target": 22
    },
    {
      "annotations": {
        "Anatomy": {
          "brain": true
        },
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Of equal importance, because GSK3β is considered to be one of the main tau kinases in vivo, the inhibition of GSK3β by cotinine may also prevent the abnormal phosphorylation of tau observed in AD brains and the consequent appearance of neuroﬁbrillary tangles of hyperphosphorylated tau [85–87].",
      "key": "2c29ea9cb626744f3ee8b515c47ad1ab",
      "line": 372,
      "relation": "increases",
      "source": 50,
      "subject": {
        "effect": {
          "name": "kin",
          "namespace": "bel"
        },
        "modifier": "Activity"
      },
      "target": 56
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Cerebral Cortex": true,
          "Hippocampus": true,
          "Hypothalamus": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 and alpha4beta2 nAChR subtypes are the most abundant of the nicotinic receptors and are fundamental for mediating working memory and attention in mammals. These receptors are localized throughout the cortex, hippocampus, amygdala, hypothalamus, striatum, and other regions involved in these cognitive processes [13].",
      "key": "99d11e4ff6d61a75e603b51e3d836b7e",
      "line": 254,
      "relation": "increases",
      "source": 28,
      "target": 17
    },
    {
      "annotations": {
        "Anatomy": {
          "striatum": true
        },
        "Confidence": {
          "High": true
        },
        "MeSHAnatomy": {
          "Amygdala": true,
          "Cerebral Cortex": true,
          "Hippocampus": true,
          "Hypothalamus": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The alpha7 and alpha4beta2 nAChR subtypes are the most abundant of the nicotinic receptors and are fundamental for mediating working memory and attention in mammals. These receptors are localized throughout the cortex, hippocampus, amygdala, hypothalamus, striatum, and other regions involved in these cognitive processes [13].",
      "key": "19a13aed47b849e7ffc8c710a49b1484",
      "line": 255,
      "relation": "increases",
      "source": 28,
      "target": 73
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Because decreased levels of these receptors have been found in AD brains [58], this reduction is considered to explain, at least in part, the cognitive deﬁcits in AD.",
      "key": "96b21992322569a10eb878801b1bf273",
      "line": 266,
      "relation": "increases",
      "source": 28,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "In an attempt to improve the cognitive abilities of AD patients with this new approach, modulators of the α7 receptors, such as 3-(2,4-dimethoxybenzylidene) anabaseine (GTS-21 or DMXB-A) [56, 67, 68], and many others, are under development or are currently being investigated in clinical trials [56, 69–71].",
      "key": "8c21767954475da152c5da89c33a25b3",
      "line": 280,
      "relation": "increases",
      "source": 12,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        },
        "Species": {
          "9606": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "In an attempt to improve the cognitive abilities of AD patients with this new approach, modulators of the α7 receptors, such as 3-(2,4-dimethoxybenzylidene) anabaseine (GTS-21 or DMXB-A) [56, 67, 68], and many others, are under development or are currently being investigated in clinical trials [56, 69–71].",
      "key": "b7d7e1e5e25332ef4784265cb5295c3d",
      "line": 281,
      "relation": "increases",
      "source": 13,
      "target": 19
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "1ee47a6be2e71d000b4193d3ac196164",
      "line": 361,
      "relation": "increases",
      "source": 39,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "5cbe0be133c30dc229ca1e0128b19bc8",
      "line": 328,
      "relation": "increases",
      "source": 45,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "961a1e27a3048948e1bf495d5f3fb45e",
      "line": 333,
      "relation": "increases",
      "source": 45,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "f005a591f26e1283e00cda30004f03b9",
      "line": 338,
      "relation": "increases",
      "source": 45,
      "target": 17
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "250c79e1948dac4ab73c8609a5c8d4d0",
      "line": 362,
      "relation": "increases",
      "source": 45,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "8989c9c23c1b79547220efa09247be1e",
      "line": 384,
      "relation": "increases",
      "source": 45,
      "subject": {
        "modifier": "Activity"
      },
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "e385430aee8c42789c13f21a4c3dfbe8",
      "line": 396,
      "relation": "increases",
      "source": 45,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "e1269ecfad3c8d0b967e8d4be78348c2",
      "line": 310,
      "relation": "decreases",
      "source": 47,
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Positive modulation of the α7 nAChRs could also explain cotinine’s positive effect on neuronal survival because the activation of Akt stimulates pro-survival proteins (e.g., Bcl-2 and the transcription factor cAMP responsive element-binding protein [CREB; Ref. 11] and inhibits the pro-apoptotic protein c-Jun Nterminal kinase (JNK) via the activation of the apoptosis signalregulating kinase (Ask) [76, 77; Figure 2].",
      "key": "504086662874c61a7edcd95b49eeea8e",
      "line": 311,
      "relation": "increases",
      "source": 51,
      "target": 26
    },
    {
      "key": "dee1f41ea3b1ac3c85bb55b2df5ffac7",
      "relation": "hasVariant",
      "source": 51,
      "target": 52
    },
    {
      "annotations": {
        "Cell": {
          "neuron": true
        },
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "7b035878d11b388d86896d01eab8acf3",
      "line": 363,
      "relation": "decreases",
      "source": 51,
      "subject": {
        "modifier": "Activity"
      },
      "target": 21
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "e24656878849a093e1c1a220ae0575c4",
      "line": 324,
      "relation": "increases",
      "source": 57,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "569ead81fa153bb328a5b9f14ba99e1c",
      "line": 329,
      "relation": "increases",
      "source": 57,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "342b388992cf80c8e620e311c4eece42",
      "line": 334,
      "relation": "increases",
      "source": 57,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "5df6c0e0af05d69ec0eb7c9223aaf1a7",
      "line": 349,
      "relation": "increases",
      "source": 57,
      "target": 37
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "2e5ce50e1728e92ed8ca2fe1a68e2513",
      "line": 350,
      "relation": "increases",
      "source": 57,
      "target": 36
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "eb026614b95d693ca40368505642466f",
      "line": 326,
      "relation": "increases",
      "source": 54,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "d800979f097fcd38333f83d3d66181f3",
      "line": 331,
      "relation": "increases",
      "source": 54,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "985f47d255d9e72684d0b5fe0419459b",
      "line": 336,
      "relation": "increases",
      "source": 54,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "6aa2242f2b6d71cfa8e04ffb6d934a3a",
      "line": 385,
      "relation": "increases",
      "source": 54,
      "subject": {
        "modifier": "Activity"
      },
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "2be1584d1e15f4b1a173d3d5640c2bf1",
      "line": 397,
      "relation": "increases",
      "source": 54,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "d38ce7f9b62d2d3110fcda108a9834fb",
      "line": 327,
      "relation": "increases",
      "source": 53,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "1d7337a7168314451847b085b2c53407",
      "line": 332,
      "relation": "increases",
      "source": 53,
      "target": 19
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, alpha7 nAChRs can favor synaptic plasticity and cognition by activating the protein kinases phosphoinositide-3 kinase [PI3K; Refs. 78, 79], Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), and the transcription factor CREB, which participate in mediating the structural and molecular changes required for learning and memory processes [80, 81].",
      "key": "466f32e16a772ac3e50dafcc2d0a01c8",
      "line": 337,
      "relation": "increases",
      "source": 53,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "4e127cd52874547b66fce9c8f7515549",
      "line": 386,
      "relation": "increases",
      "source": 53,
      "subject": {
        "modifier": "Activity"
      },
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "ebf0f52d9c5afdd369830d9b7da576c0",
      "line": 398,
      "relation": "increases",
      "source": 53,
      "target": 38
    },
    {
      "key": "23b76c45f6e32610e008760dd3887c53",
      "relation": "partOf",
      "source": 58,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The activation of PI3K heterodimers p85/p110 by the α7 receptor is triggered by the binding of p85 (the regulatory subunit) to phospho-tyrosyl proteins such as Fyn, which leads to the release of p110 [the catalytic subunit; Ref. 82].",
      "key": "191f7239eea1755a8a98202e9fdbcec2",
      "line": 344,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 31,
      "target": 57
    },
    {
      "key": "b45a768fc5558ed2e2e1dade7ccbe3eb",
      "relation": "partOf",
      "source": 49,
      "target": 31
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "04dfb0d6391170254a0566a39c2d0d5e",
      "line": 351,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 37,
      "subject": {
        "modifier": "Activity"
      },
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "0ed80a62537211ec53cc7d4b14fe5e81",
      "line": 353,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 37,
      "subject": {
        "modifier": "Activity"
      },
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "3561a42b2c7c9e725d7f3681fe0424f7",
      "line": 355,
      "relation": "increases",
      "source": 37,
      "subject": {
        "modifier": "Activity"
      },
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "2e6dbc541030e26ab419346cf49e1a8a",
      "line": 358,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 37,
      "subject": {
        "modifier": "Activity"
      },
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "986360e3edf791a579252c0711091512",
      "line": 352,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 36,
      "subject": {
        "modifier": "Activity"
      },
      "target": 39
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "46f7d32e1176e58164800058de4feb54",
      "line": 354,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 36,
      "subject": {
        "modifier": "Activity"
      },
      "target": 45
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "859009e65a548418041493bd7239ad21",
      "line": 356,
      "relation": "increases",
      "source": 36,
      "subject": {
        "modifier": "Activity"
      },
      "target": 52
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "7eac08d7a7437f5f160a3c0dd68389fc",
      "line": 359,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 36,
      "subject": {
        "modifier": "Activity"
      },
      "target": 51
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Thus, PI3K stimulates the phosphorylation of Akt at residues threonine 308 and serine 473 [83]. The active form of Akt can then promote neuronal survival by stimulating CREB and Bcl-2 activity and by inactivating Ask1 by phosphorylation at serine 83 [84].",
      "key": "6ea4017ffd2e3a31da117810135328fd",
      "line": 357,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 52,
      "target": 51
    },
    {
      "key": "064f60bbd4e86ec0d71e89e733af2e71",
      "relation": "hasVariant",
      "source": 55,
      "target": 56
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This versatile protein is believed to mediate memory storage in the brain’s active networks by coupling changes in neuronal activity patterns to diverse forms of synaptic plasticity [95].",
      "key": "50806319ffa7290db8f7a64f2af0c437",
      "line": 403,
      "relation": "increases",
      "source": 38,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This versatile protein is believed to mediate memory storage in the brain’s active networks by coupling changes in neuronal activity patterns to diverse forms of synaptic plasticity [95].",
      "key": "d1330b6da2fe0b94045094f10f622bfc",
      "line": 404,
      "relation": "increases",
      "source": 38,
      "target": 23
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Furthermore, the stimulation of both CREB and ERK1/2 by cotinine may promote the expression of activity-regulated cytoskeleton-associated protein (Arc, also termed Arg3.1), derived from an immediate early gene required for the consolidation of memory [88–90].",
      "key": "bba3c29eeba02b83c004bb9f71c9b98a",
      "line": 387,
      "relation": "increases",
      "source": 34,
      "target": 17
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "088ec032ebce5911ef3f8213faf2afe3",
      "line": 392,
      "relation": "increases",
      "source": 40,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "2b4959fda33613afb271476cd4f82b18",
      "line": 393,
      "relation": "increases",
      "source": 25,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "Arc expression is stimulated by brain-derived neurotrophic factor (BDNF), serum response element [91], NMDA receptors [92], elongation factor 2 [93], CREB, and ERK1/2 [94].",
      "key": "10fe8e86a8aab621d9ad186aecdd0c1e",
      "line": 395,
      "relation": "increases",
      "source": 48,
      "target": 38
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "The α7 receptors seem to have a clear role in mediating Arc gene expression, as an increase in levels of Arc mRNA were found in rats treated with the selective α7 receptor partial agonist SSR180711 [96].",
      "key": "0300243eb3c1064038bc36d278ab5e91",
      "line": 410,
      "relation": "positiveCorrelation",
      "source": 77,
      "target": 44
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        },
        "Disease": {
          "Alzheimer's disease": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "This concept, though still controversial, is supported by the fact that the level of soluble Abeta correlates better with dementia than does plaque burden in AD patients [101, 102].",
      "key": "84b1d38a456f3df054fc7f3d554cb8b5",
      "line": 418,
      "relation": "positiveCorrelation",
      "source": 66,
      "target": 1
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For example, some compounds such as curcumin inhibit oligomerization but not ﬁbrillation [105], and other compounds such as o-vanillin inhibit the formation of both oligomers and ﬁbrils [106]. Other molecules such as the naphthalene sulfonates inhibit ﬁbrillation but not oligomerization [107].",
      "key": "5f7be3cbd73c1d89b867d04adb07c90f",
      "line": 424,
      "relation": "decreases",
      "source": 4,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For example, some compounds such as curcumin inhibit oligomerization but not ﬁbrillation [105], and other compounds such as o-vanillin inhibit the formation of both oligomers and ﬁbrils [106]. Other molecules such as the naphthalene sulfonates inhibit ﬁbrillation but not oligomerization [107].",
      "key": "80a19c17b5ba71f8e4a61a81bad0790e",
      "line": 425,
      "relation": "causesNoChange",
      "source": 4,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For example, some compounds such as curcumin inhibit oligomerization but not ﬁbrillation [105], and other compounds such as o-vanillin inhibit the formation of both oligomers and ﬁbrils [106]. Other molecules such as the naphthalene sulfonates inhibit ﬁbrillation but not oligomerization [107].",
      "key": "12a2defd0ece45ab45e8bab4b06bcde1",
      "line": 426,
      "relation": "decreases",
      "source": 7,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For example, some compounds such as curcumin inhibit oligomerization but not ﬁbrillation [105], and other compounds such as o-vanillin inhibit the formation of both oligomers and ﬁbrils [106]. Other molecules such as the naphthalene sulfonates inhibit ﬁbrillation but not oligomerization [107].",
      "key": "617d4503e2f9e3e075f663652273f823",
      "line": 427,
      "relation": "decreases",
      "source": 7,
      "target": 9
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For example, some compounds such as curcumin inhibit oligomerization but not ﬁbrillation [105], and other compounds such as o-vanillin inhibit the formation of both oligomers and ﬁbrils [106]. Other molecules such as the naphthalene sulfonates inhibit ﬁbrillation but not oligomerization [107].",
      "key": "120a70667a076f3d6d42daa063883e9c",
      "line": 428,
      "relation": "causesNoChange",
      "source": 11,
      "target": 10
    },
    {
      "annotations": {
        "Confidence": {
          "High": true
        }
      },
      "citation": {
        "authors": [
          "Echeverria V",
          "Zeitlin R"
        ],
        "date": "2012-07-01",
        "db": "PubMed",
        "db_id": "22530628",
        "db_name": "Cotinine: a potential new therapeutic agent against Alzheimer's disease.",
        "first": "Echeverria V",
        "journal": "CNS neuroscience & therapeutics",
        "last": "Zeitlin R",
        "pages": "517-23",
        "volume": "18"
      },
      "evidence": "For example, some compounds such as curcumin inhibit oligomerization but not ﬁbrillation [105], and other compounds such as o-vanillin inhibit the formation of both oligomers and ﬁbrils [106]. Other molecules such as the naphthalene sulfonates inhibit ﬁbrillation but not oligomerization [107].",
      "key": "c2a7e8ae15678de204b1f97a6dca931c",
      "line": 429,
      "relation": "decreases",
      "source": 11,
      "target": 9
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"NMDA receptor antagonist\")",
      "concept": {
        "name": "NMDA receptor antagonist",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "98259a7a4485d8deb63c87637c5bed63"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "concept": {
        "name": "amyloid-beta",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "e9557ea6ec74113b73fe23f4bd76b524"
    },
    {
      "bel": "a(CHEBI:\"glutamate(2-)\")",
      "concept": {
        "name": "glutamate(2-)",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "f038ea8a4f75cf654709ad9030bee114"
    },
    {
      "bel": "a(CHEBI:acetylcholine)",
      "concept": {
        "name": "acetylcholine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "ff868385e5c4b568faf7e1eaa79ba0c4"
    },
    {
      "bel": "a(CHEBI:curcumin)",
      "concept": {
        "name": "curcumin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "7af57558091f98bed6718820d043f953"
    },
    {
      "bel": "a(CHEBI:memantine)",
      "concept": {
        "name": "memantine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "fbc9887dc54845a22697f68a954e7a69"
    },
    {
      "bel": "a(CHEBI:nicotine)",
      "concept": {
        "name": "nicotine",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "44ed555f78bacda2933ddef1d4280ce9"
    },
    {
      "bel": "a(CHEBI:vanillin)",
      "concept": {
        "name": "vanillin",
        "namespace": "CHEBI"
      },
      "function": "Abundance",
      "id": "94908265c1f99f4e753f392cf7304fa5"
    },
    {
      "bel": "a(CONSO:\"amyloid-beta aggregates\")",
      "concept": {
        "name": "amyloid-beta aggregates",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "cb9ddfdb593aa8073305b79828d71376"
    },
    {
      "bel": "a(CONSO:\"amyloid-beta fibrils\")",
      "concept": {
        "name": "amyloid-beta fibrils",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "b0d56b42446bae9f5fb7dbdf434d93af"
    },
    {
      "bel": "a(CONSO:\"amyloid-beta oligomers\")",
      "concept": {
        "name": "amyloid-beta oligomers",
        "namespace": "CONSO"
      },
      "function": "Abundance",
      "id": "34014daa17e0fc6d25c4a657cd071f3a"
    },
    {
      "bel": "a(DRUGBANK:\"1-Anilino-8-Naphthalene Sulfonate\")",
      "concept": {
        "name": "1-Anilino-8-Naphthalene Sulfonate",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "bd3699fc53881fe7a574c0b6809fe3a1"
    },
    {
      "bel": "a(DRUGBANK:\"GTS-21\")",
      "concept": {
        "name": "GTS-21",
        "namespace": "DRUGBANK"
      },
      "function": "Abundance",
      "id": "592ecb35a3ac32700e2737c673057e6a"
    },
    {
      "bel": "a(MESH:\"3-(4-dimethylaminobenzylidene)anabaseine\")",
      "concept": {
        "name": "3-(4-dimethylaminobenzylidene)anabaseine",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "c8efdeae7b483bbfbb9fd79dc5f056bf"
    },
    {
      "bel": "a(MESH:\"cotinine N-glucuronide\")",
      "concept": {
        "name": "cotinine N-glucuronide",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "def33fa2118860190d9a8f4cf414c696"
    },
    {
      "bel": "a(MESH:Cotinine)",
      "concept": {
        "name": "Cotinine",
        "namespace": "MESH"
      },
      "function": "Abundance",
      "id": "ac8039a6fa6e6c87cdd78e51d7a61bae"
    },
    {
      "bel": "a(PUBCHEM:10219774)",
      "concept": {
        "name": "10219774",
        "namespace": "PUBCHEM"
      },
      "function": "Abundance",
      "id": "cdc4c23c031c9a070bd22cadf2514012"
    },
    {
      "bel": "bp(GO:\"learning or memory\")",
      "concept": {
        "name": "learning or memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "f7990d886000f2ae69441a960a7d6236"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "concept": {
        "name": "neuron death",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "5af039c1f3120f7215931236c3c03804"
    },
    {
      "bel": "bp(GO:cognition)",
      "concept": {
        "name": "cognition",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "24220ec2073c35bcd945681ee9c6ea38"
    },
    {
      "bel": "bp(GO:memory)",
      "concept": {
        "name": "memory",
        "namespace": "GO"
      },
      "function": "BiologicalProcess",
      "id": "e03a718b44a1ff30acea5c31966879a9"
    },
    {
      "bel": "bp(MESH:\"Cell Survival\")",
      "concept": {
        "name": "Cell Survival",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "c6f26bea83787c63169a3fcb728da799"
    },
    {
      "bel": "bp(MESH:\"Long-Term Potentiation\")",
      "concept": {
        "name": "Long-Term Potentiation",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "00d6f15279a2d7ff5c72ffe3a624cb7f"
    },
    {
      "bel": "bp(MESH:\"Neuronal Plasticity\")",
      "concept": {
        "name": "Neuronal Plasticity",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "7e5d48cf7a27a09a15d969d961c71347"
    },
    {
      "bel": "bp(MESH:\"Sensory Gating\")",
      "concept": {
        "name": "Sensory Gating",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "94650e0f4c0e58183e199af94ea783f8"
    },
    {
      "bel": "bp(MESH:\"Serum Response Element\")",
      "concept": {
        "name": "Serum Response Element",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "0a0fca6f2e6c30c324a62826b2fa4b7f"
    },
    {
      "bel": "bp(MESH:Apoptosis)",
      "concept": {
        "name": "Apoptosis",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "c349a56d97ae2dad6eacbaaaffc859d2"
    },
    {
      "bel": "bp(MESH:Neuroprotection)",
      "concept": {
        "name": "Neuroprotection",
        "namespace": "MESH"
      },
      "function": "BiologicalProcess",
      "id": "94345c5831649e39b0f93286f5357249"
    },
    {
      "bel": "complex(CONSO:\"alpha-4 beta-2 nAChR\")",
      "concept": {
        "name": "alpha-4 beta-2 nAChR",
        "namespace": "CONSO"
      },
      "function": "Complex",
      "id": "61fa4c7307193b47b6fed6d37f5fb73c"
    },
    {
      "bel": "complex(a(CHEBI:\"amyloid-beta\"), a(CHEBI:nicotine))",
      "function": "Complex",
      "id": "ed3f201e47a40391c2cbe8a444d4f699",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "a(CHEBI:nicotine)",
          "concept": {
            "name": "nicotine",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "44ed555f78bacda2933ddef1d4280ce9"
        }
      ]
    },
    {
      "bel": "complex(a(CHEBI:\"amyloid-beta\"), p(HGNC:CHRNA7))",
      "function": "Complex",
      "id": "151487d770afc4e8298457d9611c5419",
      "members": [
        {
          "bel": "a(CHEBI:\"amyloid-beta\")",
          "concept": {
            "name": "amyloid-beta",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "e9557ea6ec74113b73fe23f4bd76b524"
        },
        {
          "bel": "p(HGNC:CHRNA7)",
          "concept": {
            "name": "CHRNA7",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "9bc1722fb5ef96f07f754ae7740789e2"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:FYN), p(HGNC:PIK3R1))",
      "function": "Complex",
      "id": "90d11c342393956af43247150c370046",
      "members": [
        {
          "bel": "p(HGNC:FYN)",
          "concept": {
            "name": "FYN",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "9aaa70667f9bfd5fd59c45422ea4c02c"
        },
        {
          "bel": "p(HGNC:PIK3R1)",
          "concept": {
            "name": "PIK3R1",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "3aee3b2c3f137d96d17459c56e459e14"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:nicotine), p(HGNC:CYP2A6))",
      "function": "Composite",
      "id": "7f76e437cf98c660b00de363bc63b348",
      "members": [
        {
          "bel": "a(CHEBI:nicotine)",
          "concept": {
            "name": "nicotine",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "44ed555f78bacda2933ddef1d4280ce9"
        },
        {
          "bel": "p(HGNC:CYP2A6)",
          "concept": {
            "name": "CYP2A6",
            "namespace": "HGNC"
          },
          "function": "Protein",
          "id": "fe7e27a46139b1bc90525c95efebd824"
        }
      ]
    },
    {
      "bel": "composite(a(CHEBI:nicotine), p(NCIT:C18024))",
      "function": "Composite",
      "id": "ef4954bc98d5221de7ae79af00922763",
      "members": [
        {
          "bel": "a(CHEBI:nicotine)",
          "concept": {
            "name": "nicotine",
            "namespace": "CHEBI"
          },
          "function": "Abundance",
          "id": "44ed555f78bacda2933ddef1d4280ce9"
        },
        {
          "bel": "p(NCIT:C18024)",
          "concept": {
            "name": "C18024",
            "namespace": "NCIT"
          },
          "function": "Protein",
          "id": "47e3b5222374cd340a69b13e31ba0da9"
        }
      ]
    },
    {
      "bel": "p(HGNC:ACR)",
      "concept": {
        "name": "ACR",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f6a109f50de540b5311db6cb92087634"
    },
    {
      "bel": "p(HGNC:AKT1)",
      "concept": {
        "name": "AKT1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "2fe8184c6afa461574b1e1fba8b00dab"
    },
    {
      "bel": "p(HGNC:AKT1, pmod(Ph, Ser, 473))",
      "concept": {
        "name": "AKT1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "21970be17a0793ac2440b382d5d9ac68",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 473
        }
      ]
    },
    {
      "bel": "p(HGNC:AKT1, pmod(Ph, Thr, 308))",
      "concept": {
        "name": "AKT1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8a010b1b2f75308ab1b1f77c2fe261a1",
      "variants": [
        {
          "code": "Thr",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 308
        }
      ]
    },
    {
      "bel": "p(HGNC:ARC)",
      "concept": {
        "name": "ARC",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f7b074862f517492ccac5ae7ed87f177"
    },
    {
      "bel": "p(HGNC:BCL2)",
      "concept": {
        "name": "BCL2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "fc778e9de9f9cebd455edd38ebaf2874"
    },
    {
      "bel": "p(HGNC:BDNF)",
      "concept": {
        "name": "BDNF",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a638d5f84b9678f17c8795852300134a"
    },
    {
      "bel": "p(HGNC:CHAT)",
      "concept": {
        "name": "CHAT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "94b2bdf537c7ffe601c2d96d694f35bf"
    },
    {
      "bel": "p(HGNC:CHRNA3)",
      "concept": {
        "name": "CHRNA3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "86c0de39fb88bd636cc77727263dabc2"
    },
    {
      "bel": "p(HGNC:CHRNA4)",
      "concept": {
        "name": "CHRNA4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "80f72d8d35ebd95851a4fbebf17fce4b"
    },
    {
      "bel": "p(HGNC:CHRNA7)",
      "concept": {
        "name": "CHRNA7",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "9bc1722fb5ef96f07f754ae7740789e2"
    },
    {
      "bel": "p(HGNC:CREBBP)",
      "concept": {
        "name": "CREBBP",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "46148e81658994544d74b5db695e5cd8"
    },
    {
      "bel": "p(HGNC:CYP2A6)",
      "concept": {
        "name": "CYP2A6",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "fe7e27a46139b1bc90525c95efebd824"
    },
    {
      "bel": "p(HGNC:DBF4)",
      "concept": {
        "name": "DBF4",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "236401dce418ab0f1a427ebb34d835aa"
    },
    {
      "bel": "p(HGNC:EEF2)",
      "concept": {
        "name": "EEF2",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3500984728e6a674139a4a5bc809b6ba"
    },
    {
      "bel": "p(HGNC:FYN)",
      "concept": {
        "name": "FYN",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "9aaa70667f9bfd5fd59c45422ea4c02c"
    },
    {
      "bel": "p(HGNC:GSK3B)",
      "concept": {
        "name": "GSK3B",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "8eaf29c9e491ff4e49619e77de92467c"
    },
    {
      "bel": "p(HGNC:MAP3K5)",
      "concept": {
        "name": "MAP3K5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "f2dc75eee6b5e335308cb999dbe95dcc"
    },
    {
      "bel": "p(HGNC:MAP3K5, pmod(Ph, Ser, 83))",
      "concept": {
        "name": "MAP3K5",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "082f04281feedd60ad5ed3be09090f00",
      "variants": [
        {
          "code": "Ser",
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 83
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPK1)",
      "concept": {
        "name": "MAPK1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "c2f6ad92491bc72d5a91676150570d38"
    },
    {
      "bel": "p(HGNC:MAPK3)",
      "concept": {
        "name": "MAPK3",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3e8019d5b20d209d67726881082657b3"
    },
    {
      "bel": "p(HGNC:MAPT)",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "7d1009217050e75d549c8c5aa83309a8"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "concept": {
        "name": "MAPT",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "a8fb3a87d5a0672c07462bb17c8b0947",
      "variants": [
        {
          "concept": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:PIK3CA)",
      "concept": {
        "name": "PIK3CA",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "62710688c60f9b65b4eb7962290db060"
    },
    {
      "bel": "p(HGNC:PIK3R1)",
      "concept": {
        "name": "PIK3R1",
        "namespace": "HGNC"
      },
      "function": "Protein",
      "id": "3aee3b2c3f137d96d17459c56e459e14"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Cholinergic receptors nicotinic subunits\")",
      "concept": {
        "name": "Cholinergic receptors nicotinic subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "8038209bc0b5bd919a7208d644f913f8"
    },
    {
      "bel": "p(HGNCGENEFAMILY:\"Glutamate ionotropic receptor NMDA type subunits\")",
      "concept": {
        "name": "Glutamate ionotropic receptor NMDA type subunits",
        "namespace": "HGNCGENEFAMILY"
      },
      "function": "Protein",
      "id": "b7afccdb6102ed56132b102ce2e5f6e6"
    },
    {
      "bel": "p(MESH:\"Neurofibrillary Tangles\")",
      "concept": {
        "name": "Neurofibrillary Tangles",
        "namespace": "MESH"
      },
      "function": "Protein",
      "id": "23b57fa4c2111fd8150d349cd2c5c2d0"
    },
    {
      "bel": "p(NCIT:C18024)",
      "concept": {
        "name": "C18024",
        "namespace": "NCIT"
      },
      "function": "Protein",
      "id": "47e3b5222374cd340a69b13e31ba0da9"
    },
    {
      "bel": "path(CONSO:Excitotoxicity)",
      "concept": {
        "name": "Excitotoxicity",
        "namespace": "CONSO"
      },
      "function": "Pathology",
      "id": "3c37b0742431ce3c53b58624adcec97c"
    },
    {
      "bel": "path(DOID:\"Alzheimer's disease\")",
      "concept": {
        "name": "Alzheimer's disease",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "bab8638a4ae2b144ee036438e0a858da"
    },
    {
      "bel": "path(DOID:\"Parkinson's disease\")",
      "concept": {
        "name": "Parkinson's disease",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "76019b99765efff85f16f73b8c6f082e"
    },
    {
      "bel": "path(DOID:dementia)",
      "concept": {
        "name": "dementia",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "12dcaf8ab5101babb7dc7b3b88e591ed"
    },
    {
      "bel": "path(DOID:schizophrenia)",
      "concept": {
        "name": "schizophrenia",
        "namespace": "DOID"
      },
      "function": "Pathology",
      "id": "e8abd22302b97ee80e32edd14cf0f8fb"
    },
    {
      "bel": "path(HP:Anxiety)",
      "concept": {
        "name": "Anxiety",
        "namespace": "HP"
      },
      "function": "Pathology",
      "id": "d6ab1a2f6a8518ad589ac17df1148bbb"
    },
    {
      "bel": "path(MESH:\"Memory Disorders\")",
      "concept": {
        "name": "Memory Disorders",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "9e4da5a1d5bd55db298a1977ac7eaf3b"
    },
    {
      "bel": "path(MESH:\"Plaque, Amyloid\")",
      "concept": {
        "name": "Plaque, Amyloid",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "ff45c3caeb411cd232d96d6ed01854d5"
    },
    {
      "bel": "path(MESH:\"Tobacco Use Disorder\")",
      "concept": {
        "name": "Tobacco Use Disorder",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "13c7264761719693573e94c72e68fb16"
    },
    {
      "bel": "path(MESH:\"Tobacco Use\")",
      "concept": {
        "name": "Tobacco Use",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "fbb8398bea10f7fdad2c83bbc2bcef3f"
    },
    {
      "bel": "path(MESH:Attention)",
      "concept": {
        "name": "Attention",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "f22e7196f5d0614ad79325e3690466ec"
    },
    {
      "bel": "path(MESH:Fear)",
      "concept": {
        "name": "Fear",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "439f87974e3b3d11dd0ef09b3a25e246"
    },
    {
      "bel": "path(MESH:Tachyphylaxis)",
      "concept": {
        "name": "Tachyphylaxis",
        "namespace": "MESH"
      },
      "function": "Pathology",
      "id": "2c5231f19cfbb525d5f2e192fa5fd317"
    },
    {
      "bel": "path(NCIT:C28004)",
      "concept": {
        "name": "C28004",
        "namespace": "NCIT"
      },
      "function": "Pathology",
      "id": "06e8c99ef94e07734d1e8bd1d7c2cb9c"
    },
    {
      "bel": "r(HGNC:ARC)",
      "concept": {
        "name": "ARC",
        "namespace": "HGNC"
      },
      "function": "RNA",
      "id": "4103b417d62bd9e69f0687b00acc9557"
    }
  ]
}